| __timestamp | Merus N.V. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 3852327 | 381287000 |
| Thursday, January 1, 2015 | 839656 | 452612000 |
| Friday, January 1, 2016 | 4478145 | 316800000 |
| Sunday, January 1, 2017 | 16432324 | 330100000 |
| Monday, January 1, 2018 | 11890871 | 265800000 |
| Tuesday, January 1, 2019 | 34110000 | 336200000 |
| Wednesday, January 1, 2020 | 35781000 | 423900000 |
| Friday, January 1, 2021 | 40896000 | 467000000 |
| Saturday, January 1, 2022 | 52200000 | 487000000 |
| Sunday, January 1, 2023 | 59836000 | 477100000 |
Unveiling the hidden dimensions of data
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of United Therapeutics Corporation and Merus N.V. from 2014 to 2023. Over this period, United Therapeutics consistently outspent Merus N.V., with SG&A expenses peaking at approximately $487 million in 2022, a 26% increase from 2014. In contrast, Merus N.V. showed a more dynamic growth, with expenses surging from under $1 million in 2015 to nearly $60 million in 2023, marking a staggering 7000% increase. This stark contrast highlights differing operational scales and strategic priorities. While United Therapeutics maintains a steady financial commitment to its operations, Merus N.V.'s rapid increase suggests aggressive expansion and investment in its growth trajectory.
Johnson & Johnson or Merus N.V.: Who Manages SG&A Costs Better?
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
United Therapeutics Corporation and Bio-Techne Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Lantheus Holdings, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Incyte Corporation and Merus N.V.
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Merus N.V. Trends and Insights
PTC Therapeutics, Inc. vs Merus N.V.: SG&A Expense Trends
Merus N.V. vs Soleno Therapeutics, Inc.: SG&A Expense Trends